Comparison of in vitro Cloning Assays for Drug Sensitivity Testing of Human Brain Tumours

References

• Von Hoff D D. Send this patient's tumour for culture and sensitivity. New Engl J Med 1983; 308: 154
   PubMed Web of Science ®Google Scholar
• Pihl A. UICC study group on chemosensitivity testing of human tumours: Problems–applications–future prospects. Int J Cancer 1986; 37: 1
   PubMed Web of Science ®Google Scholar
• Moon T E. Quantitative and statistical analysis of the association between in vitro and in vivo studies. Cloning of Human Tumour Stem Cells, S E Salmon. Alan R. Liss, New York 1980; 209
   Google Scholar
• Ali-Osman F, Bier J, Maurer H R. In vitro cytostatic drug sensitivity testing in the human tumour stem cell assay: A modified method for the determination of the sensitivity index. Tumour Diagn Ther 1983; 4: 1
   Google Scholar
• Selby P, Buick R N, Tannock I. A critical appraisal of the human tumour stem cell assay. New Engl J Med 1983; 308: 129
   PubMed Web of Science ®Google Scholar
• Bigner D D, Bigner S H, Ponten J, et al. Heterogeneity of genotypic and phenotypic characteristics of 15 permanent cell lines derived from human gliomas. J Neuro-pathol Exp Neurol 1981; 40: 201
   PubMed Web of Science ®Google Scholar
• Schilsky R L, Kelley J A, Ihde D C, Howser D M, Cordes R S, Young R C. Phase-I trial and pharmacokinetics of aziridinylbenzoquinone (NSC-182986) in humans. Cancer Res 1982; 42: 1582
   PubMed Web of Science ®Google Scholar
• Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea & Febiger 1984; 315
   Google Scholar
• Levin V A. Clinical pharmacology of the nitrosoureas. Nitrosoureas: Current Status and New Developments, A W Prestayako, S T Crooke, L H Baker, S K Carter, P S Schein. Academic Press, New York 1981; 171
   Google Scholar
• Eckhardt S, Cstenyi J, Horvath I P, et al. Uptake of labeled dianhydrogalactitol into human gliomas and nervous tissue. Cancer Treat Rep 1977; 6: 841
   Google Scholar
• Gouyette A, Huertas D, Drox J-P, Rousse J, Amiel J-L. Pharmacokinetis of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (Phase I study). Eur J Cancer Clin Oncol 1982; 18: 1985
   Google Scholar
• Ali-Osman F, Giblin J, Dougherty D V, Rosenblum M L. Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. Cancer Res 1987; 47: 3718
   PubMed Web of Science ®Google Scholar
• Rosenblum M L, Vasquez D A, Hoshino T, Wilson C B. Development of a clonogenic cell assay for human brain tumours. Cancer 1978; 41: 2305
   PubMed Web of Science ®Google Scholar
• Hamburger A W, Salmon S E. Primary bioassay of human tumour stem cells. Science 1977; 19: 461
   Google Scholar
• Courtenay V D, Mills J. An in vitro colony assay for human tumours grown in immunosuppressed mice and treated in vivo with cytotoxic agents. Br J Cancer 1978; 37: 261
   PubMed Web of Science ®Google Scholar
• Tveit K M, Endresen L, Rugstad H E, Fodstak Q, Pihl A. Comparison of two soft-agar methods for assaying chetnosensitivity of human tumours in vitro: Malignant melanomas. Br J Cancer 1981; 44: 539
   PubMed Web of Science ®Google Scholar
• West C ML, Southerland R M. A radiobiological comparison of human tumour soft-agar clonogenic assays. Int J Cancer 1986; 37: 897
   PubMed Web of Science ®Google Scholar
• Endresen L, Tveit K M, Rugstad H E, Pihl A. Chemo-sensitivity measurements of human tumour cells by soft agar assays are influenced by the culture conditions. Br J Cancer 1985; 51: 843
   PubMed Web of Science ®Google Scholar
• Hepburn P J, Masters J RW. Influence of clonogenic assay methodology on measurement of drug sensitivities in vitro. Cancer Chemother Pharmacol 1986; 16: 80
   PubMed Web of Science ®Google Scholar
• Bruce W R, Valeriote F A. Normal and malignant stem cells and chemotherapy. The Proliferation and Spread of Neoplastic Cells. M.D. Anderson Hospital and Tumour Institutes at Houston. Williams & Wilkins, Baltimore 1968; 409–20
   Google Scholar
• Linfoot P A, Gray J W, Dean N P, Marton L J, Deen D F. Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate. Cancer Res 1986; 46: 2402
   PubMed Web of Science ®Google Scholar
• Salmon S E, Hamburger A W, Soehnlen B, Durie B GM, Alberts D S, Moon T E. Quantitation of differential sensitivity of human tumour stem cells to anticancer drugs. New Engl J Med 1978; 298: 1321
   PubMed Web of Science ®Google Scholar
• Hanauske A-R, Von Hoff D D. Clinical correlations with the human tumour clonogenic assay. Cancer Invest 1985; 3: 541
   PubMed Web of Science ®Google Scholar
• Fravel H NA, Roberts J J. G1 phase Chinese hamster V79–379A cells are inherently more sensitive to platinum bound to their DNA than mid-S phase or asynchronously treated cells. Biochem Pharmacol 1979; 28: 1575
   PubMed Web of Science ®Google Scholar
• Roberts J J, Thomson A J. The mechanism of action of antitumour platinum compounds. Prog Nucleic Acid Res Mol Biol 1979; 22: 71
   PubMedGoogle Scholar
• Ali-Osman F, Rosenblum M L, Giannini D D, Levin V A. Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacologic and human tumour clonogenic cell studies. Cancer Res 1985; 45: 2988
   PubMed Web of Science ®Google Scholar
• Auclair C, Paoletti C. Bioactivation of the antitumour drugs 9-hydroxyellipticine and derivatives by a peroxi-dase-hydrogen peroxide system. J Med Chem 1981; 24: 289
   PubMed Web of Science ®Google Scholar